Bradyarrhythmias associated with sofosbuvir treatment

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1886-1888

  Fontaine, Hélène ^a   Duboc, Denis ^a   Pol, Stanislas ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DACLATASVIR; PROPRANOLOL; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADULT; AGED; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CASE REPORT; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FAINTNESS; FEMALE; HEART ATRIUM PACING; HEPATITIS C; HUMAN; IMPLANTED HEART PACEMAKER; LETTER; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINUS BRADYCARDIA; SINUS NODE DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; HEPATITIS C, CHRONIC;

AGED; AMIODARONE; ANTIVIRAL AGENTS; BRADYCARDIA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; URIDINE MONOPHOSPHATE;

EID: 84946595410     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1505967     Document Type: Letter

References (3)

1. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370: 211-21.
2. Signal de sécurité concernant l'association daclatasvir et/ou sofosbuvir, deux antiviraux dans le traitement de l'hépatite C chronique, et/ou amiodarone et la survenue d'arythmies cardiaques. January 16, 2015 (http://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite -pour-l-evaluation-des-risques-en-matiere-de-pharmacovigilance -PRAC/Finalisation-de-la-reevaluation-des-medicaments-contenant -de-l-Ambroxol-ou-de-la-bromhexine-retour-d-information-sur-le -PRAC-de-janvier-2015-Point-d-information).
3. Food and Drug Administration. FDA drug safety communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. March 24, 2015 (http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm).